Invest now
Jubilant Pharmova share price
Balanced risk
- ₹1,025.00(-0.23%)July 16, 2026 15:29:31 PM IST
- NSE
- BSE
- Vol : 291.45 K (NSE + BSE)Last 20 day avg : 141.41 K
Jubilant Pharmova is trading -0.23% lower at Rs 1,025.00 as compared to its last closing price. Jubilant Pharmova has been trading in the price range of 1,039.00 & 1,013.00. Jubilant Pharmova has given -4.18% in this year & 5.94% in the last 5 days. Jubilant Pharmova has TTM P/E ratio 32.46 as compared to the sector P/E of 25.82.There are 4 analysts who have initiated coverage on Jubilant Pharmova. There are 1 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.The company posted a net profit of 119.40 Crores in its last quarter.Listed peers of Jubilant Pharmova include Torrent Pharmaceuticals (-0.30%), Cipla (-0.69%), Sun Pharmaceutical Industries (-0.06%).The Mutual Fund holding in Jubilant Pharmova was at 8.03% in 31 Mar 2026. The MF holding has increased from the last quarter. The FII holding in Jubilant Pharmova was at 15.90% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 16 Jul 2026, 03:56 PM IST
- BetaMedium volatility1.14Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.51The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.51Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation-5.55The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Jubilant Pharmova News
Jubilant Pharmova Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals | 5,002.75 | -0.30 | 1,69,368.61 | 67.32 | 17.1 | 0.83 | 17.62 |
| Cipla | 1,428.00 | -0.69 | 1,15,360.31 | 22.95 | 3.87 | 0.87 | 0.81 |
| Sun Pharmaceutical Industries | 1,951.30 | -0.06 | 4,68,171.21 | 36.24 | 5.77 | 0.92 | 0.50 |
| Divi's Laboratories | 7,319.75 | 0.48 | 1,94,316.36 | 78.61 | 11.52 | 0.46 | 0.01 |
| Dr Reddy's Laboratories | 1,223.90 | -0.48 | 1,02,151.19 | 18.63 | 3.14 | 0.63 | 2.34 |
Mutual Fund Ownership
View allJubilant Pharmova Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-22 | Audited Results & Final Dividend |
| 2026-02-06 | Quarterly Results |
| 2025-10-31 | Quarterly Results |
| 2025-07-29 | Quarterly Results |
| 2025-05-16 | Audited Results & Final Dividend |
About the company Jubilant Pharmova
- IndustryBiotechnology & Drugs
- ISININE700A01033
- BSE Code530019
- NSE CodeJUBLPHARMA
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals, including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical businesses working to address unmet medical needs in oncology and autoimmune diseases.
Jubilant Pharmova Share Price FAQs
Jubilant Pharmova is trading at 1025.00 as on Thu Jul 16 2026 09:59:31. This is -0.23% lower as compared to its previous closing price of 1027.40.
The market capitalization of Jubilant Pharmova is 16225.53 Cr as on Thu Jul 16 2026 09:59:31.
The average broker rating on Jubilant Pharmova is Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 1 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Jubilant Pharmova is 1250.00 whereas the 52 wk low is 783.75
Jubilant Pharmova can be analyzed on the following key metrics -
- TTM P/E: 32.46
- Sector P/E: 25.82
- Dividend Yield: 0.49%
- D/E ratio: 0.51
Jubilant Pharmova reported a net profit of 398.50 Cr in 2026.
The Mutual Fund Shareholding was 8.03% at the end of 31 Mar 2026.
Quick Links
EQUITY QUICK LINKS
Jubilant Pharmova QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.